Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was $5.44 for the day, down -1.45% from the previous closing price of $5.52. In other words, the price has decreased by -$1.45 from its previous closing price. On the day, 48.08 million shares were traded. RXRX stock price reached its highest trading level at $5.76 during the session, while it also had its lowest trading level at $5.33.
Ratios:
Our analysis of RXRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.58 and its Current Ratio is at 3.58. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.07.
On May 22, 2023, Morgan Stanley started tracking the stock assigning a Equal-Weight rating and target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.Needham initiated its Buy rating on March 16, 2023, with a $17 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 23 ’25 when Gibson Christopher sold 100,000 shares for $5.70 per share. The transaction valued at 570,000 led to the insider holds 954,229 shares of the business.
Gibson Christopher bought 100,000 shares of RXRX for $570,000 on Oct 23 ’25. On Oct 10 ’25, another insider, Gibson Christopher, who serves as the Chief Executive Officer of the company, sold 100,000 shares for $6.04 each. As a result, the insider received 604,000 and left with 974,229 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 2374824192 and an Enterprise Value of 1927533184. For the stock, the TTM Price-to-Sale (P/S) ratio is 36.60 while its Price-to-Book (P/B) ratio in mrq is 2.56. Its current Enterprise Value per Revenue stands at 29.84 whereas that against EBITDA is -3.287.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.92, which has changed by -0.19061583 over the last 52 weeks, in comparison to a change of 0.18286073 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $12.36, while it has fallen to a 52-week low of $3.79. The 50-Day Moving Average of the stock is 3.16%, while the 200-Day Moving Average is calculated to be -5.16%.
Shares Statistics:
RXRX traded an average of 38.22M shares per day over the past three months and 48186360 shares per day over the past ten days. A total of 425.48M shares are outstanding, with a floating share count of 332.98M. Insiders hold about 23.39% of the company’s shares, while institutions hold 55.84% stake in the company. Shares short for RXRX as of 1760486400 were 126348417 with a Short Ratio of 3.31, compared to 1757894400 on 132044177. Therefore, it implies a Short% of Shares Outstanding of 126348417 and a Short% of Float of 31.05.
Earnings Estimates
As of right now, 6.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.15 and low estimates of -$0.42.
Analysts are recommending an EPS of between -$1.37 and -$1.8 for the fiscal current year, implying an average EPS of -$1.62. EPS for the following year is -$1.25, with 8.0 analysts recommending between -$0.81 and -$1.6.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 5 analysts. It ranges from a high estimate of $23.9M to a low estimate of $16M. As of. The current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $26.08MFor the next quarter, 5 analysts are estimating revenue of $21.7M. There is a high estimate of $37.7M for the next quarter, whereas the lowest estimate is $16M.
A total of 8 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $95.5M, while the lowest revenue estimate was $48.35M, resulting in an average revenue estimate of $71.55M. In the same quarter a year ago, actual revenue was $58.84MBased on 8 analysts’ estimates, the company’s revenue will be $103.84M in the next fiscal year. The high estimate is $208.4M and the low estimate is $60M.
